{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:27:55Z","timestamp":1762842475927,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":87,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016834","name":"Chongqing Municipal Health Commission","doi-asserted-by":"publisher","award":["2016ZDXM031"],"award-info":[{"award-number":["2016ZDXM031"]}],"id":[{"id":"10.13039\/100016834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870304"],"award-info":[{"award-number":["81870304"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2019CDYGYB019"],"award-info":[{"award-number":["2019CDYGYB019"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100368","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T19:53:33Z","timestamp":1617134013000},"page":"100368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study"],"prefix":"10.1016","volume":"27","author":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JunYong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Xian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YanPing","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XianLi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctarc.2021.100368_bib0001","doi-asserted-by":"crossref","first-page":"R305","DOI":"10.1677\/ERC-10-0187","article-title":"An update on androgen deprivation therapy for prostate cancer","volume":"17","author":"Sharifi","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100368_bib0002","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc801","article-title":"A history of prostate cancer treatment","volume":"2","author":"Denmeade","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100368_bib0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.ctarc.2021.100368_bib0004","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ctarc.2021.100368_bib0005","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2021.100368_bib0006","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","article-title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","volume":"29","author":"Hansen","year":"2018","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100368_bib0007","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eururo.2018.09.040","article-title":"Efficacy of Radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects","volume":"76","author":"Isaacsson Velho","year":"2019","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.ctarc.2021.100368_bib0008","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s00345-018-2477-2","article-title":"Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment","volume":"37","author":"Moyer","year":"2019","journal-title":"World J. Urol."},{"issue":"6","key":"10.1016\/j.ctarc.2021.100368_bib0009","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bju.15055","article-title":"The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer","volume":"125","author":"Ranasinghe","year":"2020","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100368_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.09.012","article-title":"Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer","volume":"34","author":"Boehm","year":"2016","journal-title":"Urol. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100368_bib0011","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boeve","year":"2019","journal-title":"Eur. Urol."},{"issue":"10162","key":"10.1016\/j.ctarc.2021.100368_bib0012","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ctarc.2021.100368_bib0013","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100368_bib0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2021.100368_bib0015","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100368_bib0016","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100368_bib0017","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"28","key":"10.1016\/j.ctarc.2021.100368_bib0018","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III Trial-FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100368_bib0019","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1186\/s12885-019-5974-9","article-title":"Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)","volume":"19","author":"Puente","year":"2019","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2021.100368_bib0020","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:24:00Z","timestamp":1762842240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221000666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":20,"alternative-id":["S2468294221000666"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100368","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100368"}}